Authors: Prakash, A.; Faulds, D.
Source: Drugs, Volume 55, Number 2, February 1998 , pp. 261-267(7)
Publisher: Adis International
Abstract:▴ Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition of the proton pump by rabeprazole is partially reversible.
▴ Rabeprazole has 2- to 10-fold greater antisecretory activity than omeprazole in vitro. However, it dissociates more readily from H,K-ATPase than omeprazole, resulting in a shorter duration of action.
▴ In comparative clinical trials rabeprazole was significantly more effective than placebo, famotidine or ranitidine and as effective as omeprazole in the treatment of patients with erosive or ulcerative gastro-oesophageal reflux disease or gastric or duodenal ulcers. Healing rates with rabeprazole were independent of Helicobacter pylori status.
▴ Rabeprazole in combination with either clarithromycin and metronidazole or clarithromycin and amoxicillin or amoxicillin and metronidazole or clarithromycin for 7 days produced eradication of H. pylori in 100, 95, 90 and 63% of patients.
▴ The tolerability profile of rabeprazole 20mg once daily was similar to that of famotidine 20mg twice daily, ranitidine 150mg 4 times daily or omeprazole 20mg once daily in comparative trials. The adverse events reported with once daily administration of rabeprazole 20mg include malaise, nausea, diarrhoea, headache, dizziness and skin eruptions in 0.7 to 2.2% of patients.
Keywords: Duodenal-ulcer, treatment; Gastric-ulcer, treatment; Gastro-oesophageal-reflux, treatment; New-drug-profiles; Proton-pump-inhibitors, general; Rabeprazole, adverse-reactions; Rabeprazole, antimicrobial-activity; Rabeprazole, general; Rabeprazole, pharmacodynamics; Rabeprazole, pharmacokinetics; Rabeprazole, therapeutic-use; Reviews-on-treatment
Document Type: New Drug Profile
Affiliations: Adis International Limited, Auckland, New Zealand
Publication date: February 1, 1998